Vac­cine doc­u­ments, young lead­ers and mar­ket tur­moil: End­points' 10 biggest sto­ries of 2022

It’s been a volatile year in the world of bio­phar­ma. Mar­ket de­clines re­set M&A val­u­a­tions, and may be be­gin­ning to tempt big­ger buy­ers back in­to deal­mak­ing. Rus­sia’s war in Ukraine dis­rupt­ed drug sales and clin­i­cal tri­als. A new gen­er­a­tion of young biotech lead­ers emerged in the End­points 20(+1) Un­der 40. And as cap­i­tal runs dry in a tough en­vi­ron­ment for rais­ing new funds, com­pa­nies big and small are tak­ing a look at their head­counts and op­er­a­tions for ways to make it through lean times.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER